IP Library › Granted Patent US 8,633,161
Granted Patent B2
US 8,633,161 · App. 11/909,559 · Granted Jan 21, 2014

Therapeutic agents for the treatment of leukemia

Inventors: Danilo Perrotti (Dublin, OH); Paolo Neviani (Columbus, OH); Ramasamy Santhanam (Columbus, OH); John C. Byrd (Arlington, OH); Guido Marcucci (Powell, OH); Natarajan Muthusamy (Galloway, OH); Ching-Shih Chen (Upper Arlington, OH)
Assignee: The Ohio State University Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,633,161
App. No.
11/909,559
Granted
Jan 21, 2014
Kind
B2
Abstract

The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph′-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.

Claims (5)

1. A method for treating a BCR/ABL-mediated leukemia in a mammal consisting of administering to said mammal a therapeutically effective amount of a PP2A activating compound selected from the group consisting of protamine sulfate; rolipram; butyryl-forskolin; 1,9-dideoxy-forskolin; and FTY720; wherein the PP2A activating compound is optionally administered with a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the BCR/ABL-mediated leukemia is chronic myelogenous leukemia or Philadelphia positive acute lymphoblastic leukemia.

3. The method of claim 1 , wherein the mammal is in the blast crisis stage of chronic myelogenous leukemia.

4. The method of claim 1 , wherein the mammal is resistant to imatinib therapy.

5. The method of claim 1 , wherein the mammal has refractory leukemia.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2018
From: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 045699/0348 →
CONFIRMATORY LICENSE Recorded May 10, 2011
From: THE OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026249/0526 →
CONFIRMATORY LICENSE Recorded Mar 23, 2011
From: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026001/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2008
From: PERROTTI, DANILO; NEVIANI, PAOLO; SANTHANAM, RAMASAMY; BYRD, JOHN C; MARCUCCI, GUIDO; MUTHUSAMY, NATARAJAN; CHEN, CHING-SHIH
To: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 020319/0232 →
Continuity (2)
Provisional Application 60665091 · Mar 24, 2005
Related Publication 20100256072A1 · Oct 7, 2010